简介：AbstractObjective:To investigate whether peroxisome proliferator-activated receptor γ (PPARγ) agonists, rosiglitazone and GW1929, activate the phosphatidylinositol 3-kinase (PI3K)-AKT/protein kinase B pathway and the mitogen-activated protein kinase (MAPK) /extracellular signal-regulated kinase1/2 (ERK1/2) pathway by upgrading the expression of chemerin.Methods:The HTR-8/SVneo trophoblastic cells were cultured in vitro in high glucose concentration (25 mmol/L) to mimic gestational diabetic phenotypes. We transfected small interfering RNA into HTR-8/SVneo cells to silence two receptors of chemerin, that are chemokine-like receptor 1 (CMKLR1) and G protein-coupled receptor1 (GPR1). And recombinant human chemerin, PPARγ agonists (rosiglitazone, 10 μmol/L and GW1929, 10 μmol/L) and PPARγ inhibitor (GW9662, 5 μmol/L) were additionally added to the medium, respectively. The existence of chemerin was verified by immunocytochemistry, and the expressions of PPARγ, chemerin, and its receptors as well as insulin signaling-related factors PI3K, AKT2, and MAPK (ERK1/2) were detected by real time quantitative-polymerase chain reaction and western blot.Results:Chemerin existed in the HTR-8/SVneo cells. Effects of chemerin on PI3K-AKT pathway and MAPK (ERK1/2) pathway were dependent on the density of chemerin. When rosiglitazone and GW1929 were added to the medium, the mRNA levels of PI3K, AKT2, and MAPK1 were upregulated (P < 0.05). Conversely, GW9662 downregulated the mRNA levels of AKT2 and MAPK1 (P < 0.05). Rosiglitazone and GW1929 increased the protein levels of PPARγ, chemerin, CMKLR1 and GPR1 (P < 0.05). Rosiglitazone and GW1929 had no effect on the expression of PI3K p110β and phospho-AKT2 without CMKLR1 (P > 0.05). Meanwhile, the expression of phospho-ERK2 remained unaffected in the absence of GPR1 (P > 0.05).Conclusion:Both rosiglitazone and GW1929 have the effect of improving insulin signaling pathways via upgrading the level of chemerin in high glucose treated HTR-8/SVneo cells.

简介：摘要：目的：采用优质护理策略对产科患者进行护理，帮助其顺利度过分娩过程，提升整个过程的舒适度和满意度。方法：选取2019年1月至2019年10月于本院分娩的180例孕妇作为研究对象，根据护理方式的不同将其分成两组，每组90例，对照组采用常规护理措施，观察组则采用优质护理措施，比较两组产妇的护理效果[焦虑自评量表（SAS）、抑郁自评量表（SDS）]、护理满意度。结果：观察组产妇的SAS、SDS评分分别为（29.15±2.27）分和（27.63±3.12）分，对照组分别为（33.25±2.44）分和（32.26±2.55）分，组间对比差异均有统计学意义（P

简介：Thepresentstudywasdesignedtodevelopandvalidateasensitiveandreliableultrahighperformanceliquidchromatographycoupledwithquadrupoletime-of-flightmassspectrometry(UPLC-QTOF/MS)methodtoseparateandidentifythechemicalconstituentsofQixueShuangbuTincture(QXSBT),aclassictraditionalChinesemedicine(TCM)prescription.UndertheoptimizedUPLCandQTOF/MSconditions,56componentsinQXSBT,includingchalcones,triterpenoids,protopanaxatriol,flavonesandflavanoneswereidentifiedandtentativelycharacterizedwithinarunningtimeof42min.Thecomponentswereidentifiedbycomparingtheretentiontimes,accuratemass,andmassspectrometricfragmentationcharacteristicions,andmatchingempiricalmolecularformulawiththatofthepublishedcompounds.Inconclusion,theestablishedUPLC-QTOF/MSmethodwasreliableforarapididentificationofcomplicatedcomponentsintheTCMprescriptions.

简介：AbstractBackground:Compared with human leukocyte antigen (HLA)-matched sibling donor (MSD) transplantation, it remains unclear whether haploidentical donor (HID) transplantation has a superior graft-versus-leukemia (GVL) effect for Philadelphia-negative (Ph-) high-risk B-cell acute lymphoblastic leukemia (B-ALL). This study aimed to compare the GVL effect between HID and MSD transplantation for Ph- high-risk B-ALL.Methods:This study population came from two prospective multicenter trials (NCT01883180, NCT02673008). Immunosuppressant withdrawal and prophylactic or pre-emptive donor lymphocyte infusion (DLI) were administered in patients without active graft-versus-host disease (GVHD) to prevent relapse. All patients with measurable residual disease (MRD) positivity posttransplantation (post-MRD+) or non-remission (NR) pre-transplantation received prophylactic/pre-emptive interventions. The primary endpoint was the incidence of post-MRD+.Results:A total of 335 patients with Ph- high-risk B-ALL were enrolled, including 145 and 190, respectively, in the HID and MSD groups. The 3-year cumulative incidence of post-MRD+ was 27.2% (95% confidence interval [CI]: 20.2%-34.7%) and 42.6% (35.5%-49.6%) in the HID and MSD groups (P = 0.003), respectively. A total of 156 patients received DLI, including 60 (41.4%) and 96 (50.5%), respectively, in the HID and MSD groups (P= 0.096). The 3-year cumulative incidence of relapse was 18.6% (95% CI: 12.7%-25.4%) and 25.9% (19.9%-32.3%; P = 0.116) in the two groups, respectively. The 3-year overall survival (OS) was 67.4% (95% CI: 59.1%-74.4%) and 61.6% (54.2%-68.1%; P = 0.382), leukemia-free survival (LFS) was 63.4% (95% CI: 55.0%-70.7%) and 58.2% (50.8%-64.9%; P= 0.429), and GVHD-free/relapse-free survival (GRFS) was 51.7% (95% CI: 43.3%-59.5%) and 37.8% (30.9%-44.6%; P= 0.041), respectively, in the HID and MSD groups.Conclusion:HID transplantation has a lower incidence of post-MRD+ than MSD transplantation, suggesting that HID transplantation might have a superior GVL effect than MSD transplantation for Ph- high-risk B-ALL patients.Trial registration:ClinicalTrials.gov: NCT01883180, NCT02673008.

简介：摘要目的比较非小细胞肺癌（non-smallcelllungcancer，NSCLC）患者外周血CD3+T细胞、CD4+CD25high调节性T细胞（regulatoryTcell，Tregcell）健康人的差异，并分析其临床意义。方法选取NSCLC患者和健康对照组各20例。分别抽取患者和志愿者的外周血3ml，分离其外周血单个核细胞(peripheralbloodmononuclearcell,PBMC)，采用流式细胞仪检测CD3+T细胞比例、CD4+CD25highTreg细胞比例(%)。结果健康组CD3+T细胞比例为61.52±13.46%，肺癌组CD3+T细胞比例为55.15±20.11%，两组比较无显著性差异。健康组CD4+CD25highTreg细胞的比例为2.14±0.85%；肺癌组CD4+CD25highTreg细胞的比例为2.76±0.53%，较健康人明显升高（p<0.05）。结论非小细胞肺癌患者存在免疫受损，可能对此开发有效的免疫治疗方法。

简介：Objective:Theaiminthisstudywastoidentifytheallelicfrequenciesofthechemokine(SDF1-3'A)andchemokinereceptor(CCR5△32,CCR5m303andCCR2-64I)genesresistanttoHIV-1infectionand/ordiseaseprogressioninindigenousChinesepopulations.Methods:ByusingQIAampDNABloodMiniKit,thegenomicDNAsampleswerepurifiedfromwholeperipheralbloodofhealthyindividuals(n=2067)fromHan,Uygur,MongolianandTibetanethnicgroups,aswellasHanpatientsincludingHIV-1carriers(n=330),patientswithothersexuallytransmitteddiseases(STDs,n=259)andintravenousdrugusers(IVDUs,n=125).TheallelicpolymorphismswereidentifiedbymeansofPCRorPCR-RFLPanalyses.ThesequencesofrandomlyselectedamplifiedPCRproductswerefurtherconfirmedbydirectDNAsequencing.Results:Themutantfrequencieswereidentifiedtobe0%-3.48%forCCR5△32,0%forCCR5m303,19.15%-28.79%forCCR2-64and19.10%-28.73%forSDF1-3'Aalleles,respectively,inChinesehealthyindividualsfromfourethnicgroups.Ourfindingsindicatedtheallelicfrequenciesvaryamongthedifferentethnicgroups.Furthermore,theHIV-1carriers,STDcasesandIVDUs(allofHanethnicity)werefoundtohavetheallelicfrequenciesof0%-0.19%(CCR5A32),0%(CCR5m303),19.31%-20.45%(CCR2-64)and25.61%-26.83%(SDF1-3'A)withminorvariationsintheirfrequenciesbetweenthepatientsandhealthyHangroups.TherewasnoCCR5-m303mutationfoundinanysubjectinthisstudy.Conclusion:TheexaminedsubjectsoffourChineseethnicoriginsshowedlowerfrequenciesofCCR5A32andCCR5m303alleles,buthigherfrequenciesofmutantCCR264IandSDF1-3'Aallelescomparedtothoseidentifiedinnorthern-EuropeanandAmericanCaucasians.ThesignificanceofthedifferentfrequenciesandpolymorphismsoftheaboveallelesinChinesepopulationsneedstobefurtherexaminedinHIV-1/AIDSdiseases.

简介：

简介：摘要：经导管主动脉瓣膜置换术具有创伤性小、术后并发症和致死率较低的优势，因此该手术具有极高的治疗安全性，成为了治疗复杂高危的主动脉瓣狭窄患者的主要治疗手段，根据相关学者的研究，为复杂高危主动脉瓣狭窄患者实施经导管主动脉瓣膜置换术治疗后的情况进行随访调查，证实了该手术用于治疗的安全性和与有效性。为患者实施手术治疗的时候，需要帮助患者完善各项检查，通过多学科协同评估患者的机体状态，制定合理的治疗方案，并且为患者实施个性化的护理方案，改善患者的心肾功能。护理人员需要充分了解经导管主动脉瓣膜置换术的流程、注意事项和潜在的危险，检测患者的病情，为患者术后实施呼吸支持，维持体循环等手段，降低并发症发病率。